Lv1
66 积分 2023-11-21 加入
Advances in mechanisms, combined therapeutic strategies and dual-target inhibitors for synergistic antitumor effects of HDAC and PD-1/PD-L1 pathway
14天前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
20天前
已完结
Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
20天前
已完结
KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer
1个月前
已完结
不孕合并子宫内膜异位症患者腹腔镜术后辅助不同药物治疗对妊娠结局的观察研究
1个月前
已关闭
Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial
2个月前
已完结
Cancer incidence and mortality in China, 2022
2个月前
已完结
Short-course Radiotherapy-based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial
2个月前
已完结
Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study
3个月前
已完结
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
3个月前
已完结
皖公网安备34019202002308
